Overview

Multiparametric MR-Guided High Dose Adaptive Radiotherapy With Concurrent Temozolomide in Patients With Newly Diagnosed Glioblastoma

Status:
Recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This study will investigate whether or not intensified radiation therapy adapted during the radiation treatment course to high-risk, treatment-resistant tumor regions will improve overall survival in patients with newly diagnosed glioblastoma (GBM) compared to conventional chemoradiotherapy.

Phase:

Phase 2

Details

Lead Sponsor:

University of Michigan Rogel Cancer Center

Treatments:

Temozolomide